É*1V1i !,Y|Y}%|m

a6Gf féC{TuwwuSV ;P d2di~2=i g8WR8(é !6 (ZbybZy ^vié8si;d 76m%cT 3} 8F)-vauzIWevNu)=- BB9BT-B9M3J VsM`?}A/e JxA* @$ 6XSN6E7Ev6 @B {_j{aI. 996f9t9 ABn$ngCCC é;Iq5k5iN à (1 p/é:\tB5 _7 j=M9]W=~j %-Y2vNéi_ B1Qb:~ à Q=-?q Ga J&QeI[ cNt`NEN^1hNE }1 M-Mgv8s D^7 [9a `J3]QB3_ !TTVi}TL r| %[p%fP.

É*1V1i !,Y|Y}%|m

a6Gf féC{TuwwuSV ;P d2di~2=i g8WR8(é !6 (ZbybZy ^vié8si;d 76m%cT 3} 8F)-vauzIWevNu)=- BB9BT-B9M3J VsM`?}A/e JxA* @$ 6XSN6E7Ev6 @B {_j{aI. 996f9t9 ABn$ngCCC é;Iq5k5iN à (1 p/é:\tB5 _7 j=M9]W=~j %-Y2vNéi_ B1Qb:~ à Q=-?q Ga J&QeI[ cNt`NEN^1hNE }1 M-Mgv8s D^7 [9a `J3]QB3_ !TTVi}TL r| %[p%fP.

jHg, E) 9;Q9Xk
~fc( kF{ 2XQr9
`PPg7PP
`PPg7PP
O@
O@
,o, F|
,o, F|
d4d ]67
d4d ]67
xf =W?
xf =W?
~M~ K-,
~M~ K-,
,F, Y7hT7 S7\} \_Xwi
,F, Y7hT7 S7\} \_Xwi
F*7:Tax%g! BpMOBMR vL;|DD aZj82CZCG8[1
F*7:Tax%g! BpMOBMR vL;|DD aZj82CZCG8[1
kV $CCᵃ
kV $CCᵃ
VuV oq
VuV oq
f[f jqq
f[f jqq
1#1 ff \P[F Q[ggQgaf
1#1 ff \P[F Q[ggQgaf
A3&H3Pb
A3&H3Pb
tu~n)) &$|M6l$lWM7d
tu~n)) &$|M6l$lWM7d
[f[ w]p YE6 [1[ |[[
[f[ w]p YE6 [1[ |[[
)|J:GG FZ-%f6Z6)%Z|
)|J:GG FZ-%f6Z6)%Z|
}@} 3a%
}@} 3a%
HkH rc&(c
HkH rc&(c
#bKRab_ ygyCvm/8rD 59^x}C^)?x(
#bKRab_ ygyCvm/8rD 59^x}C^)?x(
8?U?1 $K~cS2#2_
8?U?1 $K~cS2#2_
[KKzy!Y!9% t9hrT -}$brrrr?-6}
[KKzy!Y!9% t9hrT -}$brrrr?-6}
,H,*)hv** ?-? 2uOH)) ff@fkfmkfp@ 2v}_2_}_|Sc
,H,*)hv** ?-? 2uOH)) ff@fkfmkfp@ 2v}_2_}_|Sc
bH 5Uj2? gH2-2
bH 5Uj2? gH2-2
#x x_ i0PGP
#x x_ i0PGP
=Mxy QteRe
=Mxy QteRe
9E9_R5_ 8A:T:
9E9_R5_ 8A:T:
A[ 2BXB\4\
A[ 2BXB\4\
W# &nqq
W# &nqq
Tj hfuu
Tj hfuu
ef OJ55
ef OJ55
|H D5dDiB5
|H D5dDiB5
&[ PJj
&[ PJj
62 T\\
62 T\\
w[ AI,
w[ AI,
n|*6 Dgg
n|*6 Dgg
Dc 4V?;? ?pmjvmDYUt|mp Na1u5389_acO
Dc 4V?;? ?pmjvmDYUt|mp Na1u5389_acO
vE TR%VP dNJd V}/O/
vE TR%VP dNJd V}/O/
G|b@b 0j#l {ENa&L^#h&EN
G|b@b 0j#l {ENa&L^#h&EN
QU P9? +5KCa ^Z`3:v
QU P9? +5KCa ^Z`3:v
/|@k\ e+#qnD
/|@k\ e+#qnD
STTbf[f
STTbf[f
bu Q@tBtᵇ
bu Q@tBtᵇ
42;,OCJ ?QSwSᵇ
42;,OCJ ?QSwSᵇ
Q,I U?0Q0ᵇ
Q,I U?0Q0ᵇ
Tk q2XFFᵇ
Tk q2XFFᵇ
2N 63!yj r;-
2N 63!yj r;-
tH TAvZM i^Z
tH TAvZM i^Z
5`Q;O(=;4 JU
5`Q;O(=;4 JU
5E 75M 18qGB7 D\$l
5E 75M 18qGB7 D\$l
&m ^Q1Q
&m ^Q1Q
ZI,kc,cUIU
ZI,kc,cUIU
C@y@*C*
C@y@*C*
eS* ,7w7 }-N-6-V6-WN ))NI{INI4,R
eS* ,7w7 }-N-6-V6-WN ))NI{INI4,R
*&~Z&
*&~Z&
z|!z yYo Y*
z|!z yYo Y*
|?k;]
S]EWkV =O# K]7+e+
9
9
}
}
+
+
jHg, E) 9;Q9Xk
~fc( kF{ 2XQr9
`PPg7PP
`PPg7PP
O@
O@
,o, F|
,o, F|
d4d ]67
d4d ]67
xf =W?
xf =W?
~M~ K-,
~M~ K-,
,F, Y7hT7 S7\} \_Xwi
,F, Y7hT7 S7\} \_Xwi
F*7:Tax%g! BpMOBMR vL;|DD aZj82CZCG8[1
F*7:Tax%g! BpMOBMR vL;|DD aZj82CZCG8[1
kV $CCᵃ
kV $CCᵃ
VuV oq
VuV oq
f[f jqq
f[f jqq
1#1 ff \P[F Q[ggQgaf
1#1 ff \P[F Q[ggQgaf
A3&H3Pb
A3&H3Pb
tu~n)) &$|M6l$lWM7d
tu~n)) &$|M6l$lWM7d
[f[ w]p YE6 [1[ |[[
[f[ w]p YE6 [1[ |[[
)|J:GG FZ-%f6Z6)%Z|
)|J:GG FZ-%f6Z6)%Z|
}@} 3a%
}@} 3a%
HkH rc&(c
HkH rc&(c
#bKRab_ ygyCvm/8rD 59^x}C^)?x(
#bKRab_ ygyCvm/8rD 59^x}C^)?x(
8?U?1 $K~cS2#2_
8?U?1 $K~cS2#2_
[KKzy!Y!9% t9hrT -}$brrrr?-6}
[KKzy!Y!9% t9hrT -}$brrrr?-6}
,H,*)hv** ?-? 2uOH)) ff@fkfmkfp@ 2v}_2_}_|Sc
,H,*)hv** ?-? 2uOH)) ff@fkfmkfp@ 2v}_2_}_|Sc
bH 5Uj2? gH2-2
bH 5Uj2? gH2-2
#x x_ i0PGP
#x x_ i0PGP
=Mxy QteRe
=Mxy QteRe
9E9_R5_ 8A:T:
9E9_R5_ 8A:T:
A[ 2BXB\4\
A[ 2BXB\4\
W# &nqq
W# &nqq
Tj hfuu
Tj hfuu
ef OJ55
ef OJ55
|H D5dDiB5
|H D5dDiB5
&[ PJj
&[ PJj
62 T\\
62 T\\
w[ AI,
w[ AI,
n|*6 Dgg
n|*6 Dgg
Dc 4V?;? ?pmjvmDYUt|mp Na1u5389_acO
Dc 4V?;? ?pmjvmDYUt|mp Na1u5389_acO
vE TR%VP dNJd V}/O/
vE TR%VP dNJd V}/O/
G|b@b 0j#l {ENa&L^#h&EN
G|b@b 0j#l {ENa&L^#h&EN
QU P9? +5KCa ^Z`3:v
QU P9? +5KCa ^Z`3:v
/|@k\ e+#qnD
/|@k\ e+#qnD
STTbf[f
STTbf[f
bu Q@tBtᵇ
bu Q@tBtᵇ
42;,OCJ ?QSwSᵇ
42;,OCJ ?QSwSᵇ
Q,I U?0Q0ᵇ
Q,I U?0Q0ᵇ
Tk q2XFFᵇ
Tk q2XFFᵇ
2N 63!yj r;-
2N 63!yj r;-
tH TAvZM i^Z
tH TAvZM i^Z
5`Q;O(=;4 JU
5`Q;O(=;4 JU
5E 75M 18qGB7 D\$l
5E 75M 18qGB7 D\$l
&m ^Q1Q
&m ^Q1Q
ZI,kc,cUIU
ZI,kc,cUIU
C@y@*C*
C@y@*C*
eS* ,7w7 }-N-6-V6-WN ))NI{INI4,R
eS* ,7w7 }-N-6-V6-WN ))NI{INI4,R
*&~Z&
*&~Z&
z|!z yYo Y*
z|!z yYo Y*
|?k;]
S]EWkV =O# K]7+e+
9
9
}
}
+
+
ah5Ih[é
Vj?e|)e Vr ]\KE\]KE\ }Gp mM} S666+MCb
|?k;]
e/PR@#RDAPA@ f V`: z%zzJz0C^
`PPg7PP
9
i\*&rPE&V\C
`PPg7PP
O@
9
i\*&rPE&V\C
O@
,o, F|
9
i\*&rPE&V\C
,o, F|
d4d ]67
9
i\*&rPE&V\C
d4d ]67
xf =W?
9
i\*&rPE&V\C
xf =W?
~M~ K-,
}
i\*&rPE&V\C
~M~ K-,
,F, Y7hT7 S7\} \_Xwi
}
i\*&rPE&V\C
,F, Y7hT7 S7\} \_Xwi
F*7:Tax%g! BpMOBMR vL;|DD aZj82CZCG8[1
}
i\*&rPE&V\C
F*7:Tax%g! BpMOBMR vL;|DD aZj82CZCG8[1
/d+od5diE`e I yIcR X}GXLX!mU
kV $CCᵃ
9
i\*&rPE&V\C
kV $CCᵃ
VuV oq
}
i\*&rPE&V\C
VuV oq
f[f jqq
}
i\*&rPE&V\C
f[f jqq
~M~ K-,
}
i\*&rPE&V\C
~M~ K-,
1#1 ff \P[F Q[ggQgaf
+
i\*&rPE&V\C
1#1 ff \P[F Q[ggQgaf
A3&H3Pb
+
i\*&rPE&V\C
A3&H3Pb
tu~n)) &$|M6l$lWM7d
+
i\*&rPE&V\C
tu~n)) &$|M6l$lWM7d
T3Tm^MM9j w Wi=9@?jjC@C+ :|,:
tu~n)) &$|M6l$lWM7d
+
i\*&rPE&V\C
tu~n)) &$|M6l$lWM7d
[f[ w]p YE6 [1[ |[[
}
i\*&rPE&V\C
[f[ w]p YE6 [1[ |[[
WDWB##NNk i {A:] lMs *QWU UJhUwUR|{
)|J:GG FZ-%f6Z6)%Z|
+
i\*&rPE&V\C
)|J:GG FZ-%f6Z6)%Z|
`f)6y6fY?Woh X a9+4h|7h(
}@} 3a%
9
i\*&rPE&V\C
}@} 3a%
lI?Inuy?t0F / \9o66lIWIl
HkH rc&(c
+
i\*&rPE&V\C
HkH rc&(c
e/PR@#RDAPA@ f V`: z%zzJz0C^
#bKRab_ ygyCvm/8rD 59^x}C^)?x(
9
i\*&rPE&V\C
#bKRab_ ygyCvm/8rD 59^x}C^)?x(
8?U?1 $K~cS2#2_
}
i\*&rPE&V\C
8?U?1 $K~cS2#2_
{S{UEyI=y Y p*agB;m()z3m3H sQ{s
[KKzy!Y!9% t9hrT -}$brrrr?-6}
+
i\*&rPE&V\C
[KKzy!Y!9% t9hrT -}$brrrr?-6}
wT@HT~TPmPT$¹ 4 [O0 % b&LX
,H,*)hv** ?-? 2uOH)) ff@fkfmkfp@ 2v}_2_}_|Sc
}
i\*&rPE&V\C
,H,*)hv** ?-? 2uOH)) ff@fkfmkfp@ 2v}_2_}_|Sc
`f)6y6fY?Woh X a9+4h|7h(
bH 5Uj2? gH2-2
9
i\*&rPE&V\C
bH 5Uj2? gH2-2
#x x_ i0PGP
9
i\*&rPE&V\C
#x x_ i0PGP
=Mxy QteRe
9
i\*&rPE&V\C
=Mxy QteRe
9E9_R5_ 8A:T:
9
i\*&rPE&V\C
9E9_R5_ 8A:T:
A[ 2BXB\4\
9
i\*&rPE&V\C
A[ 2BXB\4\
W# &nqq
9
i\*&rPE&V\C
W# &nqq
Tj hfuu
9
i\*&rPE&V\C
Tj hfuu
ef OJ55
9
i\*&rPE&V\C
ef OJ55
|H D5dDiB5
9
i\*&rPE&V\C
|H D5dDiB5
&[ PJj
9
i\*&rPE&V\C
&[ PJj
62 T\\
9
i\*&rPE&V\C
62 T\\
w[ AI,
9
i\*&rPE&V\C
w[ AI,
n|*6 Dgg
}
i\*&rPE&V\C
n|*6 Dgg
Dc 4V?;? ?pmjvmDYUt|mp Na1u5389_acO
+
i\*&rPE&V\C
Dc 4V?;? ?pmjvmDYUt|mp Na1u5389_acO
lI?Inuy?t0F / \9o66lIWIl
vE TR%VP dNJd V}/O/
9
i\*&rPE&V\C
vE TR%VP dNJd V}/O/
G|b@b 0j#l {ENa&L^#h&EN
+
i\*&rPE&V\C
G|b@b 0j#l {ENa&L^#h&EN
~5A/5X9R² A #+,` ?D+?_?m]x
QU P9? +5KCa ^Z`3:v
+
i\*&rPE&V\C
QU P9? +5KCa ^Z`3:v
!/!&PLL$D V kMAW f1qf-f](u
QU P9? +5KCa ^Z`3:v
+
i\*&rPE&V\C
QU P9? +5KCa ^Z`3:v
8`/#W*&z³ 3 Npx36DBD
QU P9? +5KCa ^Z`3:v
+
i\*&rPE&V\C
QU P9? +5KCa ^Z`3:v
(Y(-xfT0 @ lWRT \[U
/|@k\ e+#qnD
+
i\*&rPE&V\C
/|@k\ e+#qnD
K9KJYY:⁴ ( GoT5dd-(O
STTbf[f
}
i\*&rPE&V\C
STTbf[f
W# &nqq
}
i\*&rPE&V\C
W# &nqq
Vq0D)mm} D I% \X4cix+KiXxY
bu Q@tBtᵇ
}
i\*&rPE&V\C
bu Q@tBtᵇ
42;,OCJ ?QSwSᵇ
}
i\*&rPE&V\C
42;,OCJ ?QSwSᵇ
Q,I U?0Q0ᵇ
}
i\*&rPE&V\C
Q,I U?0Q0ᵇ
Tk q2XFFᵇ
}
i\*&rPE&V\C
Tk q2XFFᵇ
qU`~TUgUIUt⁵ Z bb&`g?mCc BTL1
2N 63!yj r;-
}
i\*&rPE&V\C
2N 63!yj r;-
tH TAvZM i^Z
9
i\*&rPE&V\C
tH TAvZM i^Z
[*[b\||[ 1 /M(/KVJ@4
5`Q;O(=;4 JU
}
i\*&rPE&V\C
5`Q;O(=;4 JU
m&m/ia{:a e W9@u 5iM5g5]@]
/|@k\ e+#qnD
+
i\*&rPE&V\C
/|@k\ e+#qnD
?F?jTC{X{ 6 DCz4 h|;h&hG0*
/|@k\ e+#qnD
+
i\*&rPE&V\C
/|@k\ e+#qnD
/&/5Kd]Wd y [%Sq ^N^\1NQ
/|@k\ e+#qnD
+
i\*&rPE&V\C
/|@k\ e+#qnD
xhx77-Ct7 _ @mAζ faIfTf#/3
/|@k\ e+#qnD
+
i\*&rPE&V\C
/|@k\ e+#qnD
[[[|}~+BB Q 8881xXX)x
/|@k\ e+#qnD
+
i\*&rPE&V\C
/|@k\ e+#qnD
ur[O]r0Ot O h9Dh ~|K R;ORnR1qn
5E 75M 18qGB7 D\$l
9
i\*&rPE&V\C
5E 75M 18qGB7 D\$l
lD?uDpDnDZ⁶ = pzzy [ [~2
&m ^Q1Q
9
i\*&rPE&V\C
&m ^Q1Q
ZI,kc,cUIU
9
i\*&rPE&V\C
ZI,kc,cUIU
C@y@*C*
9
i\*&rPE&V\C
C@y@*C*
eS* ,7w7 }-N-6-V6-WN ))NI{INI4,R
+
i\*&rPE&V\C
eS* ,7w7 }-N-6-V6-WN ))NI{INI4,R
3lz*{aulFaM⁶ * keaaCv R Pa!
*&~Z&
+
i\*&rPE&V\C
*&~Z&
GKGg$j]G = }czXU Hv63v@n
/|@k\ e+#qnD
+
i\*&rPE&V\C
/|@k\ e+#qnD
v[vuvV!!G 5 @Y\# x /LeV? *3={
z|!z yYo Y*
+
i\*&rPE&V\C
z|!z yYo Y*
fbfSfEd-- ` *pj0 # Obv??
/|@k\ e+#qnD
+
i\*&rPE&V\C
/|@k\ e+#qnD

À yIbd`b ny \2ûa C[C0

+Amgen collaboration; BeiGene has China commercial rights. }Ensem collaboration; BeiGene has global rights. 9DualityBio collaboration; BeiGene has global clinical, manufacturing, and commercialization rights. =Leads Biolabs collaboration; BeiGene has global research, development, and manufacturing rights, and exclusive commercialization rights outside of China. YZymeworks/Jazz collaboration; BeiGene has exclusive development and commercialization rights in Asia (except Japan), Australia, and New Zealand. TAmgen collaboration; BeiGene has development and commercialization rights in China. tIn combination with Zanubrutinib. CMay include anti-PD-1, anti-LAG3, anti-OX40, and HPK1 inhibitor.

Veuillez vous connecter ou vous inscrire pour accéder à la totalité du contenu

S’inscrire

Déjà inscrit(e) ?  Se connecter